Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4050784 · 1 trial · 4 indications
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
Number of participants with dose-limiting toxicities (DLTs)
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module, ORR and Duration of Response (DOR) per Investigator
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4050784 (Phase 1a - Dose Escalation) | EXPERIMENTAL | Escalating doses of LY4050784 administered orally. |
| LY4050784 (Phase 1b - Dose Optimization/Part A) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally. |
| LY4050784 (Phase 1b - Dose Expansion/Part B) | EXPERIMENTAL | LY4050784 administered orally. |
| LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1 | EXPERIMENTAL | LY4050784 administered orally in combination in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
| LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2a | EXPERIMENTAL | LY4050784 administered orally in combination in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
| LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2b | EXPERIMENTAL | LY4050784 administered orally in combination in combination with pembrolizumab, paclitaxel/nab-paclitaxel and carboplatin administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| LY4050784 | DRUG | Oral |
| Pembrolizumab | DRUG | Administered IV. |
| Cisplatin | DRUG | Administered IV. |
| Carboplatin | DRUG | Administered IV. |
| Pemetrexed | DRUG | Administered IV. |
| Paclitaxel | DRUG | Administered IV. |
| Nab paclitaxel | DRUG | Administered IV. |
Inclusion Criteria: * Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration: * Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1) * Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LY4050784 is an investigational small molecule being developed for the treatment of advanced or metastatic solid tumors, including non-small cell lung cancer and SMARCA4-deficient tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LY4050784 targets SMARCA2, a protein involved in chromatin remodeling. By inhibiting SMARCA2, the drug aims to disrupt tumor cell growth in cancers that may depend on this protein, particularly those with SMARCA4 deficiency.
LY4050784 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical trials for advanced or metastatic solid tumors.
LY4050784 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is actively recruiting participants to evaluate the drug's safety and efficacy.
LY4050784 is being studied in a single Phase 1 clinical trial with the identifier NCT06561685. This trial is recruiting participants with advanced or metastatic solid tumors, including non-small cell lung cancer and SMARCA4-deficient tumors, across multiple countries including the United States, France, Germany, Japan, South Korea, and Spain.
LY4050784 is the primary name for this investigational drug. No alternative names have been reported for this compound in clinical development.